JNJ - Johnson & Johnson

NYSE - NYSE Delayed price. Currency in USD
126.83
+0.17 (+0.13%)
At close: 4:01PM EDT

127.26 +0.43 (0.34%)
Pre-market: 6:25AM EDT

Stock chart is not supported by your current browser
Previous close126.66
Open126.88
Bid126.54 x 100
Ask127.65 x 100
Day's range125.78 - 127.30
52-week range122.15 - 148.32
Volume7,501,870
Avg. volume8,031,553
Market cap340.239B
Beta0.59
PE ratio (TTM)267.57
EPS (TTM)0.47
Earnings date17 Jul 2018
Forward dividend & yield3.36 (2.57%)
Ex-dividend date2018-02-26
1y target est149.05
Trade prices are not sourced from all markets
  • Johnson & Johnson’s Revenues Continued to Rise in 1Q18
    Market Realist14 hours ago

    Johnson & Johnson’s Revenues Continued to Rise in 1Q18

    Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist19 hours ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Motley Fool20 hours ago

    Johnson & Johnson's Top-Line Growth Isn't What It Seems

    The company’s double-digit growth comes with some caveats.

  • Geron Corporation: The Clock Is Ticking
    Motley Fool21 hours ago

    Geron Corporation: The Clock Is Ticking

    Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.

  • Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
    Market Realist21 hours ago

    Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall

    As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist23 hours ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

  • 3 Things You Should Know About Today's Top Entrepreneurs
    Motley Fool2 days ago

    3 Things You Should Know About Today's Top Entrepreneurs

    A new wave of innovation will change several of America's most established industries. Here are three important takeaways for investors.

  • Motley Fool2 days ago

    Johnson & Johnson's First-Quarter 2018 Earnings Review

    We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.

  • Barrons.com3 days ago

    [$$] Square, eBay, and the Future of Money

    Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks4 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks4 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress
    Zacks4 days ago

    Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress

    The Dow experienced a particularly volatile week as earnings results took center stage.

  • Johnson & Johnson is betting on vision care and expanding beyond contacts
    CNBC4 days ago

    Johnson & Johnson is betting on vision care and expanding beyond contacts

    J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.

  • China's pharmaceutical industry is poised for major growth
    CNBC4 days ago

    China's pharmaceutical industry is poised for major growth

    There's one major industry where China could dominate both as a maker and consumer: health care.

  • Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
    Zacks5 days ago

    Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

    Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

  • 3 Drugs That Are Moving the Needle at Johnson & Johnson
    Motley Fool5 days ago

    3 Drugs That Are Moving the Needle at Johnson & Johnson

    Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.

  • Barrons.com6 days ago

    After the Bell: Dow Drops 38 Points Because…IBM

    The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.

  • Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
    CNBC6 days ago

    Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'

    "I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.

  • Reuters - UK Focus6 days ago

    Buy a pencil, educate a child: British firms boost spending on businesses doing good

    A campaign to boost British businesses with a social mission has attracted major names, from banking to pharmaceuticals, but is far from its goal of channelling 1 billion pounds ($1.4 billion) into the sector by 2020, its founders said on Wednesday. Pharmaceutical company Johnson & Johnson (NYSE: JNJ - news) , consulting firm PwC and Santander bank have signed up to the Buy Social Corporate Challenge, launched in 2016 by Social Enterprise UK (SEUK), which represents the growing sector. About a dozen companies participating in the scheme have spent a total of 45 million pounds over the last two years with organisations that aim to address social and environmental issues as well as making a profit, SEUK said on Wednesday.

  • MarketWatch6 days ago

    IBM and J&J stocks cut 100 points from Dow industrials in early trading

    The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.

  • The Wall Street Journal6 days ago

    [$$] Johnson & Johnson Raises Sales Outlook

    Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices. J&J said it planned to cut costs in its supply chain by $600 million to $800 million a year by 2022. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.

  • What to Look for as First-Quarter Earnings Hit Around the Globe
    Bloomberg7 days ago

    What to Look for as First-Quarter Earnings Hit Around the Globe

    Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.

  • Associated Press7 days ago

    UnitedHealth and Alphabet climb; Tesla and Comerica skid

    Stocks that moved substantially or traded heavily Tuesday: UnitedHealth Group Inc., up $8.23 to $238.55 The health insurer raised its annual profit forecast after a strong first quarter. Tesla Inc., down ...

  • Wall Street rises on earnings hopes, Netflix soars
    Reuters7 days ago

    Wall Street rises on earnings hopes, Netflix soars

    U.S. stock indexes rallied on Tuesday on broad-based gains while Netflix and UnitedHealth earnings impressed investors and boosted optimism about the U.S. corporate reporting season. Shares in Netflix (NFLX.O), the first of Wall Street's leading momentum stocks to report earnings, rose 9 percent to close at a record high after the video-streaming pioneer smashed analysts' quarterly subscriber estimates. Amazon.com (AMZN.O) was the S&P's biggest boost with a 4 percent jump, helped by Netflix results but also by signs the U.S. Supreme Court is hesitant to let states force out-of-state online retailers to collect sales taxes on purchases.

  • J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs
    Investor's Business Daily7 days ago

    J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs

    Johnson & Johnson nudged its 2018 sales guidance higher Tuesday as demand for cancer drugs surged in the first quarter, even as its blockbuster Remicade continued to face competitive pressure.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes